Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2004 | 03-2004 | 12-2003 | 09-2003 | 06-2003 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,660 | -4,280 | -9,350 | -6,220 | -5,310 |
| Depreciation Amortization | 530 | 260 | -1,360 | -1,610 | 300 |
| Other Working Capital | -920 | -1,120 | -480 | -580 | -1,140 |
| Other Operating Activity | 140 | -30 | 650 | 640 | 310 |
| Operating Cash Flow | $-8,910 | $-5,170 | $-10,540 | $-7,770 | $-5,840 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -370 | -70 | -80 | -10 | -2 |
| Other Investing Activity | -7,380 | 0 | -24,580 | -8,000 | 0 |
| Investing Cash Flow | $-7,750 | $-70 | $-24,660 | $-8,010 | $-2 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 23,940 | -20 | 34,110 | 13,890 | 4,650 |
| Financing Cash Flow | $23,940 | $-20 | $34,110 | $13,890 | $4,650 |
| Beginning Cash Position | 13,630 | 13,630 | 14,720 | 14,720 | 14,720 |
| End Cash Position | 20,900 | 8,350 | 13,630 | 12,820 | 13,520 |
| Net Cash Flow | $7,270 | $-5,270 | $-1,090 | $-1,890 | $-1,190 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,910 | -5,170 | -10,540 | -7,770 | -5,840 |
| Free Cash Flow | -8,910 | -5,170 | -10,540 | -7,770 | -5,840 |